Targeting Retinoid Receptors to Treat Schizophrenia: Rationale and Progress to Date

Vladimir Lerner, Peter J A McCaffery, Michael S. Ritsner*

*Corresponding author for this work

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

This review provides the rationale and reports on the progress to date regarding the targeting of retinoid receptors for the treatment of schizophrenia and schizoaffective disorder and the role of retinoic acid in functions of the normal brain, and in psychotic states. After a brief introduction, we describe the normal function of retinoic acid in the brain. We then examine the evidence regarding retinoid dysregulation in schizophrenia. Finally, findings from two add-on clinical trials with a retinoid (bexarotene) are discussed. The authors of this review suggest that targeting retinoid receptors may be a novel approach to treat schizophrenia and schizoaffective disorder. Further studies are warranted.

Original languageEnglish
Pages (from-to)269-280
Number of pages12
JournalCNS Drugs
Volume30
Issue number4
Early online date11 Mar 2016
DOIs
Publication statusPublished - 1 Apr 2016

Fingerprint

Retinoids
Schizophrenia
Tretinoin
Psychotic Disorders
Brain
Clinical Trials

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Psychiatry and Mental health
  • Clinical Neurology

Cite this

Targeting Retinoid Receptors to Treat Schizophrenia : Rationale and Progress to Date. / Lerner, Vladimir; McCaffery, Peter J A; Ritsner, Michael S.

In: CNS Drugs, Vol. 30, No. 4, 01.04.2016, p. 269-280.

Research output: Contribution to journalArticle

Lerner, Vladimir ; McCaffery, Peter J A ; Ritsner, Michael S. / Targeting Retinoid Receptors to Treat Schizophrenia : Rationale and Progress to Date. In: CNS Drugs. 2016 ; Vol. 30, No. 4. pp. 269-280.
@article{78efb16e0cbc42459bcd4410822d1a3b,
title = "Targeting Retinoid Receptors to Treat Schizophrenia: Rationale and Progress to Date",
abstract = "This review provides the rationale and reports on the progress to date regarding the targeting of retinoid receptors for the treatment of schizophrenia and schizoaffective disorder and the role of retinoic acid in functions of the normal brain, and in psychotic states. After a brief introduction, we describe the normal function of retinoic acid in the brain. We then examine the evidence regarding retinoid dysregulation in schizophrenia. Finally, findings from two add-on clinical trials with a retinoid (bexarotene) are discussed. The authors of this review suggest that targeting retinoid receptors may be a novel approach to treat schizophrenia and schizoaffective disorder. Further studies are warranted.",
author = "Vladimir Lerner and McCaffery, {Peter J A} and Ritsner, {Michael S.}",
note = "Funding No sources of funding were used to prepare the review.",
year = "2016",
month = "4",
day = "1",
doi = "10.1007/s40263-016-0316-9",
language = "English",
volume = "30",
pages = "269--280",
journal = "CNS Drugs",
issn = "1172-7047",
publisher = "Adis International Ltd",
number = "4",

}

TY - JOUR

T1 - Targeting Retinoid Receptors to Treat Schizophrenia

T2 - Rationale and Progress to Date

AU - Lerner, Vladimir

AU - McCaffery, Peter J A

AU - Ritsner, Michael S.

N1 - Funding No sources of funding were used to prepare the review.

PY - 2016/4/1

Y1 - 2016/4/1

N2 - This review provides the rationale and reports on the progress to date regarding the targeting of retinoid receptors for the treatment of schizophrenia and schizoaffective disorder and the role of retinoic acid in functions of the normal brain, and in psychotic states. After a brief introduction, we describe the normal function of retinoic acid in the brain. We then examine the evidence regarding retinoid dysregulation in schizophrenia. Finally, findings from two add-on clinical trials with a retinoid (bexarotene) are discussed. The authors of this review suggest that targeting retinoid receptors may be a novel approach to treat schizophrenia and schizoaffective disorder. Further studies are warranted.

AB - This review provides the rationale and reports on the progress to date regarding the targeting of retinoid receptors for the treatment of schizophrenia and schizoaffective disorder and the role of retinoic acid in functions of the normal brain, and in psychotic states. After a brief introduction, we describe the normal function of retinoic acid in the brain. We then examine the evidence regarding retinoid dysregulation in schizophrenia. Finally, findings from two add-on clinical trials with a retinoid (bexarotene) are discussed. The authors of this review suggest that targeting retinoid receptors may be a novel approach to treat schizophrenia and schizoaffective disorder. Further studies are warranted.

UR - http://www.scopus.com/inward/record.url?scp=84960337267&partnerID=8YFLogxK

U2 - 10.1007/s40263-016-0316-9

DO - 10.1007/s40263-016-0316-9

M3 - Article

AN - SCOPUS:84960337267

VL - 30

SP - 269

EP - 280

JO - CNS Drugs

JF - CNS Drugs

SN - 1172-7047

IS - 4

ER -